See every side of every news story
Published loading...Updated

European regulators OK Alzheimer's treatment Leqembi after initial doubts

  • The European Commission approved lecanemab to treat Alzheimer's, making it the first therapy to receive a marketing authorization in the EU.
  • Lecanemab is the first treatment option in the EU that can slow the progression of early Alzheimer's disease.
  • This decision applies to all 27 EU member states and Norway, Iceland, and Liechtenstein.
  • Shares of Biogen rose about $2 to $119 in premarket trading following the approval.
Insights by Ground AI
Does this summary seem wrong?

131 Articles

All
Left
18
Center
17
Right
6
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 44% of the sources lean Left
44% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

economiadigital.es broke the news in on Monday, April 14, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.